De Novo Development of Distal Jejunal and Duodenal Adenomas After 41 Months of Teduglutide Treatment in a Patient With Short-Bowel Syndrome: A Case Report.
duodenal adenoma
endoscopy
glucagon-like peptide 2
intestinal failure
jejunal adenoma
parenteral nutrition
short bowel syndrome
teduglutide
Journal
JPEN. Journal of parenteral and enteral nutrition
ISSN: 1941-2444
Titre abrégé: JPEN J Parenter Enteral Nutr
Pays: United States
ID NLM: 7804134
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
revised:
23
07
2020
received:
09
06
2020
accepted:
28
07
2020
pubmed:
3
8
2020
medline:
22
4
2021
entrez:
3
8
2020
Statut:
ppublish
Résumé
The glucagon-like peptide-2 (GLP-2) analogue teduglutide is a medical treatment option for patients with short-bowel syndrome-associated chronic intestinal failure. Because studies in mice have shown that GLP-2 analogues may promote the growth of colonic neoplasms, surveillance colonoscopies before and during teduglutide therapy were recommended. The occurrence of small-intestinal neoplasms has not been reported so far, except for a recent report about de novo development of hamartomatous duodenal polyps. We report a case of de novo development of small-intestinal premalignant adenomatous polyps in both bulbar duodenum and distal jejunum in a patient treated with teduglutide for 41 months. Therefore, additional endoscopic surveillance of the upper gastrointestinal tract may be advised during teduglutide therapy for early detection and removal of potential small-bowel adenomas.
Substances chimiques
Gastrointestinal Agents
0
Peptides
0
teduglutide
7M19191IKG
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
652-656Informations de copyright
© 2020 American Society for Parenteral and Enteral Nutrition.
Références
Pironi L, Arends J, Bozzetti F et al. ESPEN guidelines on chronic intestinal failure in adults. Clin Nutr. 2016;35(2):247-307.
Pape UF, Maasberg S, Pascher A. Pharmacological strategies to enhance adaptation in intestinal failure. Curr Opin Organ Transplant. 2016;21(2):147-152.
Jeppesen PB, Pertkiewicz M, Messing B et al. Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure. Gastroenterology. 2012;143(6):1473-1481.e3.
Pevny S, Maasberg S, Rieger A et al. Experience with teduglutide treatment for short bowel syndrome in clinical practice. Clin Nutr. 2019;38(4):1745-1755.
Iakoubov R, Lauffer LM, Trivedi S, Kim YI, Brubaker PL. Carcinogenic effects of exogenous and endogenous glucagon-like peptide-2 in azoxymethane-treated mice. Endocrinology. 2009;150(9):4033-4043.
Armstrong D, Forbes A, Jeppesen PB, Lee HM, Nagy P, Seidner DL. Colon polyps in patients with short bowel syndrome before and after teduglutide: post hoc analysis of the STEPS study series. Clin Nutr. 2019;39(6):1774-1777.
Pape UF, Iyer KR, Jeppesen PB et al. Teduglutide for the treatment of adults with intestinal failure associated with short bowel syndrome: pooled safety data from four clinical trials. Therap Adv Gastroenterol. 2020;13:1756284820905766.
Summary of product characteristics. European Medicines Agency. Updated April 29, 2019. Accessed June 28, 2019. https://www.ema.europa.eu/en/documents/product-information/revestive-epar-product-information_en.pdf
Ukleja A, Alkhairi B, Bejarano P, Podugu A. De novo development of hamartomatous duodenal polyps in a patient with short bowel syndrome during teduglutide therapy: a case report. JPEN J Parenter Enteral Nutr. 2018;42(3):658-660.
Pironi L, Konrad D, Brandt C et al. Clinical classification of adult patients with chronic intestinal failure due to benign disease: an international multicenter cross-sectional survey. Clin Nutr. 2018;37(2):728-738.
van Vollenhoven RF, Fleischmann RM, Furst DE, Lacey S, Lehane PB. Longterm safety of rituximab: final report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 Years. J Rheumatol. 2015;42(10):1761-1766.
Fiorentino D, Ho V, Lebwohl MG et al. Risk of malignancy with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment Registry. J Am Acad Dermatol. 2017;77(5):845-854.e5.
Jepsen JM, Persson M, Jakobsen NO et al. Prospective study of prevalence and endoscopic and histopathologic characteristics of duodenal polyps in patients submitted to upper endoscopy. Scand J Gastroenterol. 1994;29(6):483-487.
Yang J, Gurudu SR, Koptiuch C et al. American Society for Gastrointestinal Endoscopy guideline on the role of endoscopy in familial adenomatous polyposis syndromes. Gastrointest Endosc. 2020;91(5):963-982.e2.